Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
about
Down syndrome: searching for the genetic culpritsProspects for Improving Brain Function in Individuals with Down SyndromeTiming of therapies for Down syndrome: the sooner, the betterMouse models of Down syndrome as a tool to unravel the causes of mental disabilitiesAnimal models of intellectual disability: towards a translational approachPharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.The use of mouse models to understand and improve cognitive deficits in Down syndrome.Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy.The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus.A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway.The use of mouse models for understanding the biology of down syndrome and agingAging and down syndromeOverexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascadeCombined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome.HIV Tat Impairs Neurogenesis through Functioning As a Notch Ligand and Activation of Notch Signaling Pathway.Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatmentsIs it possible to improve neurodevelopmental abnormalities in Down syndrome?Dementia in people with intellectual disability: insights and challenges in epidemiological research with an at-risk population.Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β.Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down SyndromeCognitive and pharmacological insights from the Ts65Dn mouse model of Down syndromeSilencing of amyloid precursor protein expression using a new engineered delta ribozyme.Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome.Apoptosis in Down's syndrome: lessons from studies of human and mouse models.Rodent models in Down syndrome research: impact and future opportunities.Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.Tau Depletion in APP Transgenic Mice Attenuates Task-Related Hyperactivation of the Hippocampus and Differentially Influences Locomotor Activity and Spatial Memory.Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date.
P2860
Q22241596-35893B5F-5D9B-487B-8BAE-6AD220F132A2Q22252566-4AD9361E-D121-430C-B204-CF3A0B43D00DQ26779297-2FE1476C-230C-4CC5-A269-25496E8398CDQ26863005-6AB2F95E-7725-4F3A-BE9D-882BEF420016Q28389500-B2B52EDF-B1C9-48F6-AB79-B24FA51CBD58Q30422188-C183CEE3-FC0B-4B70-A3BA-4F13215687B9Q30474023-E2088649-2EB1-4834-B2DF-9790D831176CQ30552384-FFCC6FD9-ED14-47E4-8480-D2B4D7313704Q34477111-DC250986-CEA5-420D-8216-82461361DB4BQ35003193-0D4A7C7D-60E7-4A77-914F-6B3BAAB12935Q35810481-18E20DBE-C810-482E-8FB5-7A9A0375494FQ36104322-D75F3ACA-F31D-4D0D-AB84-7AD5E09BF120Q36371958-D37ECCA1-5885-4AF2-BBE8-A0ECF37C21B0Q37399704-D3E80F9D-6EC6-452A-A7CB-2B11C5AB1283Q37490454-82102EA7-CFB8-4EC3-9A5C-081598A1B28BQ37730984-95F7E9EB-83E5-4982-B39F-4C214DEAA8FEQ37912174-156DC94D-F4DC-49E2-99F4-A3295D15F41FQ38178376-84428200-3601-479B-8FCF-6C8BEB8DEB30Q38230384-83DCC311-2BA4-4058-8F2F-AB9935F51914Q38982671-38C8E1F9-43F3-488E-88B2-BE8A98DA9D5DQ41811378-E13BBE10-B922-467F-A0FB-76F8D05385ECQ41841425-54F0253A-A2BC-4CF2-968E-3C09D6F1C5F6Q42519840-61672D00-7DAB-468A-8A1B-C8C5A52B9FD0Q43723779-195D6E82-03E2-4244-B37A-B1676D703009Q46193918-E3680040-D52F-4A36-8EF0-4F4D7AFDEB69Q50202346-3FC738E6-C11D-4418-949D-F0BC3513FD6DQ51762679-EE866E49-AE3E-45C0-8DBD-671F7CAB1D84Q53081143-FDA7E3C9-38E3-4681-A0CA-B984C870C834
P2860
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@ast
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@en
type
label
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@ast
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@en
prefLabel
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@ast
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@en
P2093
P2860
P50
P1433
P1476
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.
@en
P2093
Jacqueline Blundell
Karen Duff
William J Netzer
P2860
P304
P356
10.1371/JOURNAL.PONE.0010943
P407
P577
2010-06-03T00:00:00Z